Limula has received previous funding from FIT, including a Tech Grant and a Tech Seed loan, and is now building four advanced prototypes for testing in 2025.
Company Description
Limula offers an automated production solution to reduce costs and decentralise the manufacture of cell and gene therapies, enabling more patients to access these revolutionary treatments.